scientific

Boston Scientific reports profit in Q4

Read this article:
Boston Scientific reports profit in Q4

{ 0 comments }

Here is a good article from %sourceexcerpt%

More here: American Diabetes Association Announces Tamara Darsow, PhD, as New Vice President, Research Programs

Industry-News.org finds the best stories around the globe and distributes them to our readers. Most articles are published by third parties and these links will take you to other websites. In some cases, websites require their own registration to read their stories.

The headlines are provided as a service to readers. All rights reserved by source. We provide special newsletters on Distressed Debt and Loan Sales News, Distressed Multifamily Real Estate, Distressed Commercial Real Estate, Distressed Funds, Jobs & Employment Newsletter, Fundraising Newsletter, Deals Newsletter, Institutional News, Bankrupsky News, Distressed Housing and Condomimun News, Distressed Legal News, Hedge Fund Conferences Newsletters, Real Estate Conferences Newsletter

Other Partner & Related Sites:

Institutional Partners Jobs www.InstitutionalPartners.com: Real Estate Jobs, Private Equity Jobs, Hedge Fund Jobs

Distressed Marketplace www.DistressedMarketplace.com: Distressed Loans, Distressed Funds, Distressed Real Estate, Distressed Companies: Distressed Distressed Asset Coalition (DAC) www.DistressedCoalition.com: Debt, Distressed Real Estate, REO, Foreclosures, Distressed Funds, Distressed Loan Sales;

Distressed Events: www.Distressed-Events.com distressed-conferences, distressed webinars, distressed classes, distressed debt information, distressed real estate

Certified Courses: www.Certified-Courses.com: Leading e-learning classes on Real Estate, private Equity, Hedge Funds

Global Financial Radio www.GlobalFinancialRadio.com: Industry news for commercial real estate, distressed debt, private equity firms, hedge funds

If you want to add a news site, remove a site, or partner with us, email newspartners@industry-partners.org

www.Industry-Partners.org We Find The News For You!

{ 0 comments }

Spencer Pharmaceutical Inc. Announces Dr. Abderrazzak Merzouki Joins the Scientific Advisory Board and Business Advisor

October 28, 2010

BOSTON, MA–(Marketwire – October 28, 2010) – Spencer Pharmaceutical Inc. ( PINKSHEETS : SPPH ) announced today the addition of Dr. Abderrazzak Merzouki to join its Scientific Advisory Board as well as accepting a position as a business advisor with the company. 

Read the full article →

Spencer Pharmaceutical Appoints Critical Member to Its Scientific Advisory Board

August 30, 2010

BOSTON, MA–(Marketwire – August 30, 2010) –  Spencer Pharmaceutical Inc. ( PINKSHEETS : SPPH ) announces the appointment of Dr. Le Tien Canh, PhD to its Scientific Advisory Board.

Read the full article →

Stellar Biotechnologies Appoints John S. Sundsmo, Ph.D. to VP, Research & IP Management and Daniel C. Adelman, M.D. as Member of SAB

June 29, 2010

PORT HUENEME, CA–(Marketwire – June 29, 2010) –   Stellar Biotechnologies, Inc. ( PINKSHEETS : SBOTF ) ( TSX-V : KLH ) has appointed John S. Sundsmo, Ph.D., VP – Research & Intellectual Property Management and Daniel C. Adelman, M.D. as a member of the Scientific Advisory Board.

Read the full article →

Stellar Biotechnologies Appoints John S. Sundsmo, Ph.D. to VP, Research & IP Management and Daniel C. Adelman, M.D. as Member of SAB

June 29, 2010

PORT HUENEME, CA–(Marketwire – June 29, 2010) –   Stellar Biotechnologies, Inc. ( PINKSHEETS : SBOTF ) ( TSX-V : KLH ) has appointed John S. Sundsmo, Ph.D., VP – Research & Intellectual Property Management and Daniel C. Adelman, M.D. as a member of the Scientific Advisory Board.

Read the full article →

Gulf Oil Leak Estimate Doubled by U.S. Scientists to 40,000 Barrels a Day

June 11, 2010

By Jessica Resnick-Ault June 11 (Bloomberg) — BP Plc ’s damaged well in the Gulf of Mexico has been leaking twice as much oil as previously estimated, a team of government scientists said in its latest report on the size of the worst spill in U.S. history. The well is gushing 20,000 to 40,000 barrels of oil a day, according to an estimate released yesterday by the scientists, tasked by the government with calculating the flow. On May 27, the group pegged the rate at 12,000 to 19,000 barrels a day. The latest figure is for the size of the leak prior to June 3, when BP sawed off a bent riser pipe, potentially increasing the amount of crude escaping by as much as 20 percent. The scientists don’t have a projection for the current flow, Marcia McNutt , director of the U.S. Geological Survey, said in a news conference yesterday. “Our scientific analysis is still a work in progress, as you can tell from a range of estimates,” said McNutt, who is overseeing several independent flow-rate teams using different methods. Two offered revised flow models which were higher than those presented two weeks ago, she said. Another two are revising their data and will deliver their figures by the end of the month. Preliminary figures from a team of Woods Hole Oceanographic Institution scientists suggest the well could be leaking as much as 50,000 barrels a day, McNutt said. An accurate estimate of the volume is vital for those responding to the spill, according to U.S. Coast Guard Admiral Thad Allen . BP is capturing about half of the new estimated flow rate from the broken well, almost a mile down on the seabed of the Gulf of the Mexico, and siphoning it to ships on the surface. Bigger Than Valdez The “most credible estimate” for the size of the leak before the riser pipe was cut is 20,000 to 40,000 barrels a day, McNutt said. Her team hasn’t yet calculated the volume beyond June 3. Based on the midpoint of the latest approximation of 30,000 barrels, from April 22 when the Deepwater Horizon rig sank until June 3 the well gushed 1.26 million barrels of oil, or 52.9 billion gallons. The Exxon Valdez spilled an estimated 257,000 barrels in 1989. At a daily rate of 30,000 barrels, or 1.3 million gallons, the BP Macondo well disaster would generate that much every 8.5 days. On June 3, BP sawed off the riser pipe that had been kinked near the seafloor, constricting the flow of oil from the leak. The clean cut allowed the company to secure a containment cap to the pipe, capturing some of the escaping oil and funneling it to ships at the surface. Higher Flow Rate BP suggested that cutting the pipe may have increased the flow rate by 20 percent. McNutt said her teams of scientists are still trying to calculate how much the volume might have changed since that operation. BP collected 15,520 barrels of crude at the surface between noon on June 9 and noon on June 10, the last 24-hour period for which data is available. According to the midpoint of the latest estimates from the group of scientists, this would be about half of the oil being released each day. The first ship positioned to capture the oil is able to collect 18,000 barrels a day. By next week, BP will raise that capacity by 55 percent to 28,000 barrels in total, Allen said yesterday in a press conference. “We’re locked into a recovery mode that is way under capacity for what’s really coming out,” Ian MacDonald, an oceanographer at Florida State University in Tallahassee, said an interview after yesterday’s announcement. MacDonald has estimated the well to be leaking 26,500 to 30,000 barrels a day, six times more than the figure that BP and the government used from April 28 to May 27. 50,000 Barrels a Day? “A reasonable estimate is 22,000 barrels a day to 30,000 barrels a day,” said Tad Patzek , chair of petroleum and geosystems engineering at the University of Texas at Austin. “I don’t think 40,000 barrels a day. If BP starts recovering 28,000 barrels a day, then I will revise my estimate.” A spill rate of 50,000 barrels a day is supported by an April 27 BP memo made public on May 27 by Congressman Edward Markey , a Massachusetts Democrat, Florida State University’s MacDonald said. The memo included data on how BP had arrived at its high projection of 14,286 a day. BP assumed the oil was far thinner on the surface than it was, MacDonald said. “BP fully supported this effort to establish the new estimates,” Max McGahan, a spokesman for the London-based company, said in a telephone interview. BP provided the scientific team with data and video, he said. Each of the scientific methods being used has biases, which may shape the results they produce, McNutt said. After BP has captured all of the flow, scientists will be able to determine which methodologies were most accurate and what the biases were. “We will be able to do a much better job next time,” she said. To contact the reporter on this story: Jessica Resnick-Ault in New York at jresnickault@bloomberg.net

Read the full article →

BP Oil Leak Estimate Is Doubled by U.S. Scientists to 40,000 Barrels a Day

June 11, 2010

By Jessica Resnick-Ault June 11 (Bloomberg) — BP Plc ’s damaged well in the Gulf of Mexico has been leaking twice as much oil as previously estimated, a team of government scientists said in its latest report on the size of the worst spill in U.S. history. The well is gushing 20,000 to 40,000 barrels of oil a day, according to an estimate released yesterday by the scientists, tasked by the government with calculating the flow. On May 27, the group pegged the rate at 12,000 to 19,000 barrels a day. The latest figure is for the size of the leak prior to June 3, when BP sawed off a bent riser pipe, potentially increasing the amount of crude escaping by as much as 20 percent. The scientists don’t have a projection for the current flow, Marcia McNutt , director of the U.S. Geological Survey, said in a news conference yesterday. “Our scientific analysis is still a work in progress, as you can tell from a range of estimates,” said McNutt, who is overseeing several independent flow-rate teams using different methods. Two offered revised flow models which were higher than those presented two weeks ago, she said. Another two are revising their data and will deliver their figures by the end of the month. Preliminary figures from a team of Woods Hole Oceanographic Institution scientists suggest the well could be leaking as much as 50,000 barrels a day, McNutt said. An accurate estimate of the volume is vital for those responding to the spill, according to U.S. Coast Guard Admiral Thad Allen . BP is capturing about half of the new estimated flow rate from the broken well, almost a mile down on the seabed of the Gulf of the Mexico, and siphoning it to ships on the surface. Bigger Than Valdez The “most credible estimate” for the size of the leak before the riser pipe was cut is 20,000 to 40,000 barrels a day, McNutt said. Her team hasn’t yet calculated the volume beyond June 3. Based on the midpoint of the latest approximation of 30,000 barrels, from April 22 when the Deepwater Horizon rig sank until June 3 the well gushed 1.26 million barrels of oil, or 52.9 billion gallons. The Exxon Valdez spilled an estimated 257,000 barrels in 1989. At a daily rate of 30,000 barrels, or 1.3 million gallons, the BP Macondo well disaster would generate that much every 8.5 days. On June 3, BP sawed off the riser pipe that had been kinked near the seafloor, constricting the flow of oil from the leak. The clean cut allowed the company to secure a containment cap to the pipe, capturing some of the escaping oil and funneling it to ships at the surface. Higher Flow Rate BP suggested that cutting the pipe may have increased the flow rate by 20 percent. McNutt said her teams of scientists are still trying to calculate how much the volume might have changed since that operation. BP collected 15,520 barrels of crude at the surface between noon on June 9 and noon on June 10, the last 24-hour period for which data is available. According to the midpoint of the latest estimates from the group of scientists, this would be about half of the oil being released each day. The first ship positioned to capture the oil is able to collect 18,000 barrels a day. By next week, BP will raise that capacity by 55 percent to 28,000 barrels in total, Allen said yesterday in a press conference. “We’re locked into a recovery mode that is way under capacity for what’s really coming out,” Ian MacDonald, an oceanographer at Florida State University in Tallahassee, said an interview after yesterday’s announcement. MacDonald has estimated the well to be leaking 26,500 to 30,000 barrels a day, six times more than the figure that BP and the government used from April 28 to May 27. 50,000 Barrels a Day? “A reasonable estimate is 22,000 barrels a day to 30,000 barrels a day,” said Tad Patzek , chair of petroleum and geosystems engineering at the University of Texas at Austin. “I don’t think 40,000 barrels a day. If BP starts recovering 28,000 barrels a day, then I will revise my estimate.” A spill rate of 50,000 barrels a day is supported by an April 27 BP memo made public on May 27 by Congressman Edward Markey , a Massachusetts Democrat, Florida State University’s MacDonald said. The memo included data on how BP had arrived at its high projection of 14,286 a day. BP assumed the oil was far thinner on the surface than it was, MacDonald said. “BP fully supported this effort to establish the new estimates,” Max McGahan, a spokesman for the London-based company, said in a telephone interview. BP provided the scientific team with data and video, he said. Each of the scientific methods being used has biases, which may shape the results they produce, McNutt said. After BP has captured all of the flow, scientists will be able to determine which methodologies were most accurate and what the biases were. “We will be able to do a much better job next time,” she said. To contact the reporter on this story: Jessica Resnick-Ault in New York at jresnickault@bloomberg.net

Read the full article →

Nate Royalty Joins AgraQuest as New Director of Entomology

April 7, 2010

AgraQuest Continues Expanding Its Scientific Capabilities

Read the full article →

Merck KGaA to Buy Millipore for $6 Billion in Cash, Beating Thermo Fisher

February 28, 2010

By Zachary R. Mider and Angela Cullen March 1 (Bloomberg) — Merck KGaA agreed to buy Millipore Corp. , a supplier of drug development equipment for biotechnology companies, for about $6 billion in cash, beating a rival offer from Thermo Fisher Scientific Inc. Merck will pay $107 a share, the Darmstadt, Germany-based company said in a statement today. The offer is 13 percent more than Millipore’s closing price on Feb. 26, and 50 percent higher than the closing price on Feb. 19, the last day of trading before Bloomberg reported Millipore got a takeover bid . Merck , the world’s largest maker of liquid crystals used to make flat-panel televisions, will get about 35 percent of its revenue from chemicals after the Millipore acquisition, up from about 25 percent currently, Merck spokeswoman Phyllis Carter said today in an interview. Merck will also gain Millipore’s expertise in testing and manufacturing biotechnology drugs, said Deutsche Bank analyst Ross Muken . “The angle for Merck is access to high-growth biologics,” Muken said in a telephone interview today. Millipore allows Merck, seller of the cancer drug Erbitux outside the U.S., an opportunity to expand into biotechnology “without the pipeline risk,” said Muken, who has a “hold” rating on Millipore and doesn’t own shares in the company. Millipore, based in Billerica, Massachusetts, put itself up for sale after getting an unsolicited takeover bid worth less than $95 a share from Thermo Fisher, said people with knowledge of the matter. General Electric Co. is among other companies that weighed a bid during the auction, which was run by Goldman Sachs Group Inc., these people said. Long-Term Debt Millipore had long-term debt of $890 million, according to a Feb. 2 regulatory filing. Merck valued its acquisition at about $7.2 billion, including debt. Merck will use a bridge loan provided by Bank of America Corp., BNP Paribas and Commerzbank AG to help finance the acquisition, Merck’s Carter said. “This is a combination with an excellent strategic fit, which will allow us to cover the entire value chain for our pharma and biopharma customers, offering integrated solutions beyond chemicals,” said Dr. Karl-Ludwig Kley , chairman of the executive board of Merck, in a joint statement with Millipore today. Millipore is well-positioned in the market for researching and producing biotechnology drugs, the companies said in their statement. Merck will also gain Millipore’s comprehensive range of products , technologies and services used by drug companies and universities to improve lab productivity and manufacturing, the companies said. ‘Full Work Flow’ “Millipore can offer a full work flow for a biotech customer,” Deutsche Bank’s Muken said. “They probably have the widest array of products for that biomanufacturing market of any other players out there.” Last year, Millipore generated sales of US$ 1.7 billion, with around 6,000 employees in more than 30 countries, the companies said in their statement. Merck said last year it was seeking acquisitions to bolster its chemicals business as margins from liquid crystals slipped to less than 50 percent. Merck is being advised on Millipore by Guggenheim Securities and Perella Weinberg Partners. Millipore will contribute immediately to core earnings per share and generate cost synergies of about $100 million a year three years after the closing of the deal, Merck’s Carter said. “Today’s announcement, which is the outcome of a thorough strategic review process, is a validation of the tremendous value of the Millipore brand and a testament to the value this transformation has created for all of our stakeholders,” Martin Madaus , Chairman, President and CEO of Millipore said in the joint statement today. “We are excited to join a high-quality company like Merck as we will gain greater scale and scope in the life science industry.” To contact the reporters on this story: Zachary Mider in New York at zmider1@bloomberg.net Angela Cullen in Frankfurt at acullen8@bloomberg.net ;

Read the full article →

Atossa Genetics, Inc. Appoints Edward Sauter, M.D., Ph.D., to Its Scientific Advisory Board

February 25, 2010

SEATTLE, WA–(Marketwire – February 25, 2010) –  Atossa Genetics, Inc., a privately-held healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer, including the FDA approved Mammary Aspirate Specimen Cytology Test (MASCT) System, announced today that Edward Sauter, M.D., Ph.D., associate dean for research at the University of North Dakota School of Medicine and Health, has joined Atossa’s Scientific Advisory Board.

Read the full article →

Boston Scientific reaches $1.73b settlement with J&J

February 2, 2010

Boston Scientific reaches $1.73b settlement with J&J

Read the full article →

Sustainable Power Corp. Board of Directors Appoints Michael Garjian as Chairman of the Board, Chief Technology Officer, and Vice-Chairman of the…

December 28, 2009

BAYTOWN, TX–(Marketwire – December 28, 2009) – Sustainable Power Corp. ( PINKSHEETS : SSTP ) announced today that its Board of Directors has appointed Michael Garjian as Chairman of the Board, Chief Technology Officer, and Vice-Chairman of the Scientific and Technical Advisory Board. Following this board action, John H. Rivera, SSTP’s majority stockholder, announced the transfer, by proxy, of all his stock voting rights to Mr. Garjian. “With this action, I am excited and confident that SSTP will continue to achieve everything I have been hoping for during my decades of development work,” announced Rivera, who is now focusing his efforts on innovations that will further the success of SSTP.

Read the full article →

Pachauri Defends UN Climate Science as E-Mail Leak Raises Accuracy Concern

December 7, 2009

By Alex Morales and Kim Chipman Dec. 7 (Bloomberg) — Rajendra Pachauri , the top United Nations climate-change scientist, said the panel he heads is “transparent and objective,” dismissing allegations by global- warming skeptics that UN data were manipulated. The UN Intergovernmental Panel on Climate Change concluded in 2007 that global warming is “unequivocal” and rising human greenhouse-gas emissions were “very likely” the main cause. E-mails stolen from computer servers of the University of East Anglia in England and posted worldwide on blogs show climate researchers discussed keeping some scientific papers out of the IPCC’s report, which has formed the basis for two years of UN-led climate-treaty talks among 192 nations. The university has said the e-mails were taken out of context and that allegations about manipulation are unfounded. Speaking today during the opening session of the global summit in Copenhagen that aims to devise a deal to fight climate change, Pachauri said he had confidence in his panel’s work. The IPCC’s report is “based on measurements made by many independent institutions worldwide that demonstrate significant changes on land, in the atmosphere, the oceans and in the ice- covered areas of the earth,” he said. The study was subject to “extensive and repeated review by experts as well as governments,” with 2,500 expert reviewers, Pachauri said. Skeptics of man’s contribution to global warming, including former Senate Environment and Public Works Committee staff member Marc Morano , have cited the e-mails as evidence of a conspiracy to manipulate findings about climate change. U.S. Senator James Inhofe , a Republican from Oklahoma, has called for hearings to determine if taxpayer-funded research was altered. In one of the e-mails, Phil Jones , professor of the University of East Anglia’s Climatic Research Unit, talks about working to keep some scientific papers out of consideration for inclusion in the IPCC report, “even if we have to redefine what the peer-review literature is.” Jones has since stepped down from his role pending the outcome of an investigation. “The internal consistency from the multiple lines of evidence strongly supports the work of the scientific community, including those individuals singled out in these e-mail exchanges,” Pachauri, 69, said. The IPCC assessment process “is designed to ensure consideration of all relevant scientific information from established journals with robust peer-review processes,” Pachauri said. “There is full opportunity for experts in the field to draw attention to any piece of published literature.” To contact the reporter on this story: Alex Morales in Copenhagen via amorales2@bloomberg.net Kim Chipman in Copenhagen at KChipman@bloomberg.net

Read the full article →

Glaxo, Human Genome Say Lupus Treatment Helped Patients in Yearlong Study

October 20, 2009

By Trista Kelley and Elizabeth Lopatto Oct. 20 (Bloomberg) — GlaxoSmithKline Plc and Human Genome Sciences Inc. said their experimental lupus drug significantly reduced patients’ symptoms 16 weeks into a yearlong trial, pushing Human Genome shares up 4.9 percent in New York trading. The 865-patient study, known as Bliss-52, found that a higher dose of the Benlysta drug started benefiting patients 16 weeks into the trial. Improvement was sustained for both a higher and lower dose from weeks 24 and 28, respectively, for the duration of the 52-week test, according to data presented today at the Scientific Meeting of the American College of Rheumatology in Philadelphia. Initial trial results released in July found that Benlysta was more effective at easing pain, hair loss and skin rash than a placebo. Human Genome Sciences shares more than tripled to their greatest increase since the stock began trading in 1993 on the data. The positive overview surprised analysts, who cited disappointing earlier clinical trials and a history of failures for treatments of lupus, which causes the immune system to attack healthy cells. The rate of improvement found in the results released today was “generally consistent” across different groups of patients, researchers said. “You can see the whole curve, and those benefits emerged at 16 weeks into treatment,” Barry Labinger , the chief commercial officer for Human Genome Sciences, said in an interview yesterday. “Getting a benefit over placebo so soon is impressive.” Shares Rise Human Genome rose 4.9 percent to $21.90 in early trading at 8:37 a.m., after rising as much as 7.8 percent to $22.50. The Rockville, Maryland-based company traded as low as 45 cents on March 11. Benlysta, known chemically as belimumab, may become the first new drug in 50 years for the autoimmune disease and bring in annual peak sales of $3.5 billion by 2015 to London-based Glaxo and Human Genome, according to Panmure Gordon analyst Savvas Neophytou . “We think sales could be a billion plus,” Human Genome’s Labinger said. “How much plus is our question.” Patients in the study received one of two doses of the drug or a placebo. At the lower dose, 51.4 percent of patients showed improved symptoms compared with 43.6 percent who took the placebo, the companies said today. At a higher dose, 57.6 percent had improved symptoms, according to the company. If Benlysta succeeds in its next trial, Bliss-76, the companies plan to apply in the first half of 2010 for approval to sell it in the U.S., Europe and other countries. Human Genome hasn’t made a pricing decision yet, but other autoimmune treatments could act as a guide, Labinger said. Biologics for rheumatoid arthritis cost $15,000 to $20,000 for a single patient for a year. For multiple sclerosis, biologic drugs cost $25,000 to $30,000. 200,000 Patients There are about 320,000 lupus patients in the U.S. who are managed by rheumatologists, the companies said. About two-thirds of those patients, or 200,000, would be candidates for the drug. It would be used by those who have stopped responding to standard therapies, the companies said in a statement. Human Genome is conducting Bliss-76, a 76-week trial of Benlysta. Both studies are being conducted under a “special protocol assessment” from the U.S. Food and Drug Administration, which allows a drugmaker to work with the agency to design a late-stage clinical trial with scientific goals that, if met, would be sufficient for marketing approval. Results of Bliss-76 are expected on Nov. 2. To contact the reporter on this story: Trista Kelley in London at tkelley2@bloomberg.net

Read the full article →

Sirona Biochem Adds French Patenting ‘Top Gun’ Lawyer to Its Scientific Advisory Board

September 29, 2009

VANCOUVER, BC–(Marketwire – September 29, 2009) – Mark Senner, President, Reports: Sirona Biochem Corp. ( TSX-V : SBM ), an emerging biotech company focused on diabetes and obesity, announced today the first major appointment to its Scientific Advisory Board, patent lawyer Jacques Warcoin, CEO of Cabinet Regimbeau in Paris, France. M. Warcoin filed the first biotechnology patent in France 31 years ago and heads up a 180-person patent law firm in Paris. At the heart of his success is the belief that you ‘have to stay on top of the science until your retirement.’

Read the full article →

Ventana Appoints Vijay Guptha to Scientific Advisory Board

August 3, 2009

Ventana Appoints Vijay Guptha to Scientific Advisory Board

Read the full article →